% | $
Quotes you view appear here for quick access.

Zalicus AŞ Message Board

  • scistats scistats Jun 14, 2013 3:53 AM Flag

    Relevare's N-type calcium channel antagonist Leconotide moves forward into Phase 2a for cancer pain.

    Meanwhile, other researchers are continuing to derive potential therapeutics from cone snails. Conus catus, for example, a close relative of Prialt’s source C. magus, yields a toxin that the Australia-based company Relevare Pharmaceuticals has developed into an intravenous treatment called Leconotide. The drug blocks the same channel as Prialt and is currently in Phase 1 trials. And in January this year, Kineta announced that it has obtained the rights from the University of Utah’s "Baldomero Olivera", who isolated the molecule that became Prialt, to advance a portfolio of drug candidates based on another snail venom-derived compound, Conotoxin Rg1a, for the treatment of chronic pain.

    Leconotide (CNSB004), an N-type calcium channel antagonist, represents a systemically-administered analgesic for the treatment of severe pain that cannot be relieved effectively with strong opioid drugs and current adjuvant therapies. Relevare Pharmaceuticals™' animal data provides compelling evidence indicating that CNSB004's analgesic activity is significantly potentiated when co-administered with opioid or certain non-opioid analgesics.

    A placebo-controlled Phase IIa clinical trial of CNSB004 in cancer patients with intractable severe pain is positioned to commence in the near future.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Sci (et al): I like your posts a lot, when you stick to have a great mind.
      Very few people discuss science here (except Ving and a couple of others), as most here on this message board are not science people

      • 2 Replies to ranger43a
      • Sci,
        I'll reluctantly concur with Ranger however in your very next post you do the same thing that leads you into trouble. You infer that "the Leconotide story is LIKELY being followed closely by Mark & Justin". You have no proof yet you lay it out there in a fashion that leads people to believe what you're saying is true. I'm not saying they aren't watching it but what I do know is that YOU DON"T KNOW. It's your inferences and conjecture that you use so well to easily mislead people. You lead them along on a path where you really have no knowledge. .....and you know it!


      • Thanks Ranger, the board is diverse in its expertise and background and collectively makes a nice resource when firing on all cylinders. The developing Leconotide story is likely being carefully watched by Mark and Justin. I am inclined to believe that this factored into Justin's comments to Garrett when he said they expect one of the Z160 trials to succeed. Mark allowing wiggle room for which to announce first is good. They think Z160 is at least as good as Leconotide, and they have carefully chosen their indications. Success is just 1 pain scale point beyond placebo or 30% improvement. Prialt and Z160 are using different pain scales which is ok, but it suggests that Z160 is targeting minor pain rather than opioid breakthrough pain. Its all good. I am gaining confidence that Z160 can play a role in pain management. Exactly what that role is and its extent is yet to be determined. Its market impact will have to play out based on what it can do, but any significant contribution without side effects is a home run.

        Sentiment: Strong Buy

    • Leconotide was efficacious alone, but more so when it was given in combination with a potassium channel opener (flupirtine). The study also showed that leconotide, unlike currently available treatments of this type, does not have to be administered directly into the spinal fluid to achieve pain relief, and so could have the potential to be delivered via nasal spray, transdermal patch, or pill.

      Sentiment: Strong Buy